Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val Gebski

Showing results (181-190 of 248) with videos related to

Pageof 25
Sort By:
BMC Cancer|August 20, 2021
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancerAndrew Oar, Mark Lee, Hien Le, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|November 2, 2021
Neurodevelopmental outcomes of preterm infants after randomisation to initial resuscitation with lower (FiO<sub>2</sub> <u><</u>0.3) or higher (FiO<sub>2</sub> <u>></u>0.6) initial oxygen levels. An individual patient meta-analysisJu Lee Oei, Vishal Kapadia, Yacov Rabi, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2012
Recruitment and results of a pilot trial of vitamin D supplementation in the general population of AustraliaBich Tran, Bruce K Armstrong, John B Carlin, et al.
Diabetes & Vascular Disease Research|July 19, 2021
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-studyKwok-Leung Ong, Liang Wu, Andrzej S Januszewski, et al.
Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.
British Journal of Cancer|February 12, 2016
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trialNiall C Tebbutt, Timothy J Price, Danielle A Ferraro, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
BMJ Open|March 3, 2021
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trialVisalini Nair-Shalliker, David P Smith, Val Gebski, et al.
BMC Cancer|May 4, 2021
Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoringYoo Young Dominique Lee, Doan Trang Nguyen, Trevor Moodie, et al.
Lancet (London, England)|December 8, 2023
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm studyGregory Bruce Mann, Anita Rohini Skandarajah, Nicholas Zdenkowski, et al.
Pageof 25

Showing results (181-190 of 248) with videos related to

Sort By:
Pageof 25
BMC Cancer|August 20, 2021
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancerAndrew Oar, Mark Lee, Hien Le, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|November 2, 2021
Neurodevelopmental outcomes of preterm infants after randomisation to initial resuscitation with lower (FiO<sub>2</sub> <u><</u>0.3) or higher (FiO<sub>2</sub> <u>></u>0.6) initial oxygen levels. An individual patient meta-analysisJu Lee Oei, Vishal Kapadia, Yacov Rabi, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2012
Recruitment and results of a pilot trial of vitamin D supplementation in the general population of AustraliaBich Tran, Bruce K Armstrong, John B Carlin, et al.
Diabetes & Vascular Disease Research|July 19, 2021
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-studyKwok-Leung Ong, Liang Wu, Andrzej S Januszewski, et al.
Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.
British Journal of Cancer|February 12, 2016
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trialNiall C Tebbutt, Timothy J Price, Danielle A Ferraro, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trialGary Wittert, Karen Bracken, Kristy P Robledo, et al.
BMJ Open|March 3, 2021
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trialVisalini Nair-Shalliker, David P Smith, Val Gebski, et al.
BMC Cancer|May 4, 2021
Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoringYoo Young Dominique Lee, Doan Trang Nguyen, Trevor Moodie, et al.
Lancet (London, England)|December 8, 2023
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm studyGregory Bruce Mann, Anita Rohini Skandarajah, Nicholas Zdenkowski, et al.
Pageof 25